Atractylenolide II

Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity[1][2][3][4].

Product Specifications

CAS Number

[73069-14-4]

Product Name Alternative

Asterolide

UNSPSC

12352005

Target

Akt; Apoptosis; ERK; p38 MAPK; Src; STAT

Type

Natural Products

Related Pathways

Apoptosis; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Atractylenolide-II.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C(C)=C(C[C@@]23[H])[C@@](C[C@@]3(C)CCCC2=C)([H])O1

Molecular Formula

C15H20O2

Molecular Weight

232.32

References & Citations

[1]Ye Y, et al. Atractylenolide II induces G1 cell-cycle arrest and apoptosis in B16 melanoma cells. J Ethnopharmacol. 2011 Jun 14;136 (1) :279-82.|[2]Fu XQ, et al. Inhibition of STAT3 signalling contributes to the antimelanoma action of atractylenolide II. Exp Dermatol. 2014 Nov;23 (11) :855-7.|[3]Zhang N, et al. Two new compounds from Atractylodes macrocephala with neuroprotective activity. J Asian Nat Prod Res. 2017 Jan;19 (1) :35-41.|[4]Song X, et al. Atractylenolide II ameliorates myocardial fibrosis and oxidative stress in spontaneous hypertension rats. Technol Health Care. 2024;32 (1) :131-142.